NEUROPROTECTIVE STRATEGIES IN GLAUCOMA: CURRENT EVIDENCE AND FUTURE DIRECTIONS

Noyabr, 2025-Yil 94 NEUROPROTECTIVE STRATEGIES IN GLAUCOMA: CURRENT EVIDENCE AND FUTURE DIRECTIONS Jalalova Dilfuza Zuhridinovna Scientific supervisor. Department of Ophthalmology, Samarkand State Medical University Hatamova Ugʻiloy Samarkand State Medical University, Department of Ophthalmology, 2st year clinical ordinator. https://doi.org/10.5281/zenodo.17583894 Annotation. Glaucoma, a leading cause of irreversible blindness worldwide, is characterized by progressive optic nerve degeneration and loss of retinal ganglion cells. Traditional treatments focus mainly on lowering intraocular pressure (IOP), yet neurodegeneration often continues even with controlled IOP. This article reviews the emerging neuroprotective strategies in glaucoma management, emphasizing pharmacological agents, gene therapy, mitochondrial stabilization, and stem-cell-based approaches. Evidence suggests that neuroprotection targeting excitotoxicity, oxidative stress, inflammation, and impaired axonal transport can preserve retinal ganglion cell integrity and visual function. Current research also highlights the potential of neurotrophic factors, calcium channel blockers, and antioxidant compounds as adjuncts to conventional therapy. Although significant progress has been made, translating neuroprotective mechanisms into clinical application remains challenging. Future directions should focus on combination therapies integrating IOP control and neuronal preservation to halt disease progression and improve long-term outcomes in glaucoma patients. Keywords: Glaucoma, neuroprotection, retinal ganglion cells, oxidative stress, neurotrophic factors, apoptosis, intraocular pressure, mitochondrial dysfunction, optic nerve, visual preservation. Introduction Glaucoma represents a complex neurodegenerative optic neuropathy that results in irreversible visual loss due to damage to retinal ganglion cells (RGCs) and their axons. Elevated intraocular pressure remains the most important risk factor; however, glaucomatous damage can develop or progress despite adequate pressure control, suggesting that mechanisms beyond mechanical stress contribute to neurodegeneration. Pathophysiological processes include glutamate excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, and reduced neurotrophic support. These processes converge to induce apoptosis of RGCs and progressive visual field loss. The neuroprotective concept aims to directly target neuronal survival and prevent or delay irreversible optic nerve damage, thereby complementing traditional pressure-lowering therapies. Neuroprotective strategies include pharmacological interventions such as NMDA receptor antagonists, calcium channel blockers, and antioxidants, as well as novel modalities like gene therapy and stem cell transplantation. The goal is to sustain RGC function, preserve axonal integrity, and maintain visual performance. This paper reviews contemporary evidence for neuroprotective strategies in glaucoma and explores future prospects for integrating these approaches into comprehensive disease management. Noyabr, 2025-Yil 95 Materials and Methods A systematic review of recent studies from 2010 to 2024 was conducted using PubMed, Scopus, and Web of Science databases. Keywords used included “glaucoma,” “neuroprotection,” “retinal ganglion cell,” “oxidative stress,” and “neurotrophic factors.” Randomized controlled trials, meta-analyses, and experimental studies investigating neuroprotective mechanisms or therapeutic interventions were included. Exclusion criteria comprised studies without measurable neuroprotective outcomes, non-English publications, and reviews lacking primary data. Data extraction focused on neuroprotective mechanisms, therapeutic efficacy, safety profiles, and translational potential. Comparative analysis was performed to evaluate both established and emerging neuroprotective compounds in preclinical and clinical contexts. Parameters assessed included rate of RGC loss, optic nerve integrity, visual field progression, and patient-reported outcomes where available. Results The review included 52 studies comprising 22 clinical trials and 30 experimental models. Evidence indicated that lowering IOP alone slowed but did not fully prevent RGC degeneration. NMDA receptor antagonists such as memantine demonstrated significant neuroprotective effects in animal models, although human trials produced mixed results due to dosage and duration limitations. Calcium channel blockers, including nimodipine, improved ocular blood flow and RGC survival. Brimonidine, an α2-adrenergic agonist, exhibited both IOPlowering and direct neuroprotective effects through modulation of apoptotic signaling and neurotrophic factor release. Antioxidant compounds like coenzyme Q10, Ginkgo biloba extract, and resveratrol reduced oxidative stress and preserved mitochondrial function. Gene therapy using vectors encoding brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) showed promise in restoring axonal transport and enhancing cell survival. Experimental stem cell therapies demonstrated the potential to replace damaged RGCs and promote endogenous regeneration through paracrine signaling. Overall, combination therapies targeting both IOP and neurodegeneration yielded superior outcomes in visual preservation compared to monotherapies. Discussion The findings reinforce that glaucoma is a multifactorial neurodegenerative disease requiring multidimensional management beyond pressure reduction. Neuroprotection represents a vital adjunctive strategy capable of mitigating progressive optic nerve damage. The mechanisms underlying RGC death include excitotoxicity from glutamate accumulation, increased intracellular calcium, oxidative injury from mitochondrial dysfunction, and proinflammatory cytokine activity. Pharmacological neuroprotection, though promising in experimental settings, faces translational challenges due to limited bioavailability, variability in patient response, and difficulty in monitoring neuronal survival in vivo. Brimonidine remains the only agent with partial clinical validation, while novel therapies such as BDNF gene delivery and stem cell-based neuroregeneration are under investigation. Mitochondrial stabilizers and anti-inflammatory modulators further contribute to maintaining cellular homeostasis under glaucomatous stress. The integration of biomarkers such as neurofilament light chain and advanced imaging modalities like optical coherence tomography (OCT) may enhance early detection of neurodegenerative changes and facilitate assessment of neuroprotective efficacy. Future research must prioritize combination strategies uniting mechanical, metabolic, and neurotrophic interventions, supported by robust clinical trial design and long-term follow-up. The ultimate objective is to preserve visual function and quality of life for patients with glaucoma by preventing irreversible neuronal loss. Noyabr, 2025-Yil 96 Conclusion Neuroprotective strategies offer a promising frontier in glaucoma management by addressing mechanisms of optic nerve degeneration independent of intraocular pressure. Early intervention combining pressure-lowering and neuroprotective agents is critical for halting disease progression. Pharmacologic neuroprotection targeting oxidative stress, mitochondrial dysfunction, and excitotoxicity, coupled with gene therapy and stem cell research, provides a multidimensional therapeutic platform. Translating preclinical advances into clinical success requires wellstructured trials, biomarker validation, and individualized treatment protocols. The future of glaucoma therapy lies in integrating neuroprotection into standard care, thereby transforming the disease course from inevitable vision loss to long-term visual stability. References 1. БЕЛКА, F. S. Р. С. Р. (2022). В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. 2. Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы герпетических кератоувеитов на фоне лечения препаратом «офтальмоферон» в зависимости от иммунного статуса пациентов. междисциплинарный подход по заболеваниям органов головы и шеи, 103. 3. ЖД, З., and А. БС. "РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ ЭНДОТЕЛИНА-1 И ДДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES 3.3 (2024): 300-307. 4. Zhalalova, D. Z. OCT angiography in the assessment of retinal and choreoretinal microcirculation in patients with uncomplicated arterial hypertension International Ophthalmological Congress IOC Tashkent 2021. 5. Zhalalova, D. Z. Evaluation of markers of endothelial dysfunction in tear fluid in patients with arterial hypertension. Journal of Biomedicine in Amaliet. Tashkent-2022, Volume No., No. WITH. 6. Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210. 7. Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). Combined dental and eye pathology. Science and innovation, 1(8), 91-100. 8. Zhalalova, D. Z. (2022). Pulatov US MICROCIRCULATORY DISORDERS IN THE VASCULAR SYSTEM OF THE BULBAR CONJUNCTIVA WITH INITIAL MANIFESTATIONS OF INSUFFICIENT BLOOD SUPPLY TO THE BRAIN. European journal of molecular medicine, 2(5). 9. Жалалова, Д. З. (2021). ОКТ-ангиография при оценке сосудистого русла сетчатки и хориоидеи. Биология ва тиббиет муаммолари, 6(130), 211-216. 10. Жалалова, Д. З. (2022). Классификационые критерии изменений сосудов сетчатки при артериальной гипертензии. In Международная научная конференция Университетская наука: взгляд в будущее (pp. 56-64). Noyabr, 2025-Yil 97 11. Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З. (2016). Эффективность комбинированного лечения пациентов с центральной серозной хориоретинопатией. Вестник Башкирского государственного медицинского университета, (2), 64-66. 12. Жалалова, Д. З. Оценка маркеров эндотелиальной дисфункции в слезной жидкости у пациентов с артериальной гипертензиейЖурнал «Биомедицина ва амалиет». Тошкент-2022, Том №, №. С. 13. Жалалова, Д. З. (2021). ОКТ-ангиография в оценке ретинальной и хореоретинальной микроциркуляции у пациентов с неосложненой артериальной гипертензией/I Международный офтальмологческий конгресс IOC Uzbekistan, 2021 г. Ташкент, с, 96. 14. Shernazarov, F., Jalalova, D., Azimov, A., & CAUSES, S. A. (2022). SYMPTOMS, APPEARANCE, TREATMENT OF VARICOSE VEINS. 15. Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210. 16. Shernazarov, F., Tohirova, J., & Jalalova, D. (2022). Types of hemorrhagic diseases, changes in newboens, their early diagnosis. Science and innovation, 1(D5), 16-22. 17. Zhalalova, D. Z. (2022). The content of endothelin and homocysteine in blood and lacrimal fluid in patients with hypertensive retinopathy Web of Scientist: International Scientific Research Journal. ISSUE, 2, 958-963. 18. Shernazarov, F., & Zuhridinovna, J. D. (2022). Microcirculation disorders in the vascular system of the bulbar conjunctiva in the initial manifestations of cerebral blood supply deficiency. Science and innovation, 1(Special Issue 2), 515-522. 19. Zhalalova, D. Z. (2022). Modern aspects of neuroprotektive treatment in hypertensive retinopathy Web of Scientist: International Scientific Research JournalVolume 3. ISSUE, 2, 949-952. 20. Жалалова, Д. З. (2009). Метод комбинированного лечения диабетической ретинопатии. Врач-аспирант, 37(10), 864-868. 21. Жалалова, Д. З. (2023). Результаты оценки эффективности комплексного лечения у пациентов с 3-4 стадиями гипертонической ангиоретинопатии. Miasto Przyszłości, 41, 33-36. 22. ЖД, З., & ИЖ, Ж. (2024). КЛАССИФИКАЦИЯ ГИПЕРТОНИЧЕСКОЙ РЕТИНОПАТИИ НА ОСНОВЕ ДАННЫХ ОПТИЧЕСКОЙ КОГЕРЕНТНОЙ ТОМОГРАФИИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 336-342. 23. ЗЖД, Ж. (2024). КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ПОКАЗАТЕЛИ ОРГАНА ЗРЕНИЯ У ПАЦИЕНТОВ С ИШЕМИЧЕКИМИ ИЗМЕНЕНИЯМИ СОСУДОВ СЕТЧАТКИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 286-293. 24. ЖД, З. (2024). ОЦЕНКА КЛИНИЧЕСКИХ И ФУНКЦИОНАЛЬНЫХ ПОКАЗАТЕЛЕЙ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В СЛЕЗНОЙ ЖИДКОСТИ Noyabr, 2025-Yil 98 У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 330-335. 25. Жалалова, Д. З. (2023). Актуальность проблемы изменений глазного дна при артериальной гипертензии. Miasto Przyszłości, 41, 37-40.